A large percentage of patients prescribed the biotech's lone drug stop taking it early. Can two changes to its dosing protocols solve that problem? An alarming number of patients prescribed Nerlynx -- ...

Difficult year for Biotechnology so far, down -17% YTD. Fundamentally the sector is gaining strength. Meaningful policy clarity to be achieved in 6-weeks based on election outcome. Biotechnology is ...

ROTTERDAM, The Netherlands, September 10 /PRNewswire/ -- arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) ...

Like a lot of biotech companies, Tempe, AZ-based Capstone (CAPS) Therapeutics has high hopes for its mid-stage program. If its Phase II trial of AZX100 for scar reduction produces promising ...

I'm a little tardy on this, and, ok, it's a bit of a dry subject, so let me get right down to brass tacks. Biotech drugs are more expensive than regular old small molecule drugs, sometimes up to ...